Effect of cyproterone/acetate (SH-714) on plasma prolactin in patients with prostatic cancer.
Plasma prolactin was measured in 10 patients with prostatic cancer during treatment with cyproterone acetate (300 mg/week i.m.) Prolactin was assayed during a six month period at weekly intervals during the first 4 weeks and then at monthly intervals. Orchiectomy was not carried out. After 6 months prolactin levels were elevated compared with pre-treatment levels. It is concluded from this study that cyproterone acetate interferes with prolactin secretion by the pituitary gland.
D000368:Aged; D003534:Cyproterone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017373:Cyproterone Acetate; D006801:Humans; D008297:Male; D008875:Middle Aged; D010902:Pituitary Gland / Q000187:drug effects / Q000378:metabolism; D011388:Prolactin / Q000097:blood*; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D013997:Time Factors
D017373:Cyproterone Acetate; D011388:Prolactin; D003534:Cyproterone